Table 3. Frequency-domain results: cross-spectral analysis.

	LF Control (8)	HF Control (8)	HF Treatment (8)	rLF Treatment (5)
Frequency (Hz)	0.1 ± 0.01	0.25 ± 0.01	0.25 ± 0.01	0.044 ± 0.012
Phase (deg)	−65.1 ± 18.2	−28.5 ± 29.9	−50.5 ± 44.7	−125.2 ± 39.7
Coherence	0.76 ± 0.15	0.85 ± 0.11	0.82 ± 0.19	0.64 ± 0.15
TFG (ms mmHg-1)	9.18 ± 4.48	9.69 ± 5.0	6.5 ± 4.8*	6.26 ± 4.6

Mean values ± s.d. of frequency, phase, coherence and transfer function gain (TFG) between RR and SP, in low (LF), high (HF) and reduced-low-frequency (rLF) range. Control, before administration of urapidil and angiotensin II; Treatment, during administration of urapidil and angiotensin II. Number of subjects indicated in parentheses. LF waves were not seen during the treatment, and rLF waves were seen only during the treatment (see text).

^*P < 0.05.